<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00632281</url>
  </required_header>
  <id_info>
    <org_study_id>IRB # 502-2005</org_study_id>
    <nct_id>NCT00632281</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiation Therapy (SBRT) for Lung Tumors</brief_title>
  <official_title>Stereotactic Body Radiation Therapy for Tumors in the Thorax</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine if Stereotactic Body Radiation
      Therapy(SBRT) is a good way to treat tumors near the thorax. Stereotactic Body Radiation
      Therapy (SBRT) is a general term for a group of techniques that are designed to deliver
      radiation therapy in a way that damages normal tissues less than conventional radiotherapy.
      The two features that distinguish SBRT from conventional therapy are procedures that decrease
      errors in patient positioning and technology that results in a radiation dose distribution
      that conforms more tightly to the tumor target. Patients will receive either 48 Gy or 60 Gy
      fractions depending on the type of tumor. The majority of patients will be treated in 1 week,
      Monday through Friday, with Wednesday off.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stereotactic Body Radiotherapy (SBRT) for tumors in the thorax is a relatively new therapy in
      the United States, but has been used extensively in Japan for more than 10 years. This
      protocol seeks to enroll patients in three broad categories based on histology and clinical
      scenario: primary therapy for non-small-cell lung cancer (NSCLC), primary therapy to thoracic
      metastases, and retreatment of previously irradiated tumors or lung.

      Primary lung tumors

      Several studies have been published describing the utility of Stereotactic Body Radiotherapy
      (SBRT) for primary untreated lung tumors. In the United States, the most influential has been
      the experience of Robert Timmerman at the University of Indiana (7). They enrolled 37
      patients in a dose escalation trial of SBRT for T1 N0 and T2 N0 patients with Non-small-cell
      lung cancer (NSCLC). The trial began with 24 Gy given in 3 fractions and escalated to 60 Gy
      given in 3 fractions. Dose limited toxicity (DLT) was defined as any grade 3 pulmonary,
      esophageal, cardiac, or pericardial toxicity, or any grade 4 toxicity that was ascribed to
      the protocol treatment using the Common Toxicity Criteria from the National Cancer Institute.
      The maximum tolerated dose (MTD) was defined at dose where less and 2 of 5 enrolled patients
      experienced DLT. The MTD was not determined by this trial as this criteria was not met in the
      enrolled patients. Of the 37 patients, 2 experienced Grade 3 toxicity. One patient
      experienced pneumonitis and other patient experienced hypoxemia. Both patients responded to
      therapy and made full recoveries. There were no long term complications reported from the
      treatment at a mean follow-up of 15 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Status</measure>
    <time_frame>2 yrs</time_frame>
    <description>2-year local control (Percentage of tumors that did not recur at treated site 2 years after treatment), cause-specific survival (percentage of patients who had not died from disease under study in the 2 years since treatment), overall survival (percent of patients still alive at 2 years after treatment), and freedom from failure (percentage of patients in whom the disease treated had not progressed or recurred in the 2 years since treatment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity ot the Thorax</measure>
    <time_frame>up to 2 years, 9 months</time_frame>
    <description>Toxicity is defined as adverse events described in the CTCAE (version 3). Acute toxicity refers to adverse events that occurred up until 3 months after treatment and &quot;late&quot; toxicity as those occurring 3 months or longer after the end of treatment. Below are the Rates of grade 2 acute toxicity, grade 3 acute toxicity, late grade 3 toxicity, and late grade 4 toxicity</description>
  </secondary_outcome>
  <enrollment type="Actual">38</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy</intervention_name>
    <description>Prescription dose: 48 Gy or 60 Gy RT</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent to participate in this protocol

          -  Patients of all ages are eligible

          -  All tumor types are eligible

          -  Patients with prior thoracic radiotherapy and/or surgery are eligible

          -  Tumor size â‰¤ 5 cm

        Exclusion Criteria:

          -  The subject is eligible for surgical resection or prefers treatment on this protocol
             to surgical resection.

          -  Less than 1 year since original radiation to thorax for retreatment patients.

          -  More than 2 tumors requiring SBRT

          -  The patient cannot be positioned reproducibly due to pain or other factors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Amdur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida- Radiation Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida Shands Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 29, 2008</study_first_submitted>
  <study_first_submitted_qc>March 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2008</study_first_posted>
  <results_first_submitted>December 1, 2011</results_first_submitted>
  <results_first_submitted_qc>January 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 20, 2012</results_first_posted>
  <last_update_submitted>January 17, 2012</last_update_submitted>
  <last_update_submitted_qc>January 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Patients Receiving SBRT to Thorax</title>
          <description>22 patients had Non-small-cell lung cancer (NSCLC), 6 had metastatic disease, and 6 had 2 lesions treated simultaneously.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Patients Receiving SBRT to Thorax</title>
          <description>22 patients had Non-small-cell lung cancer (NSCLC), 6 had metastatic disease, and 6 had 2 lesions treated simultaneously.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.3" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease Status</title>
        <description>2-year local control (Percentage of tumors that did not recur at treated site 2 years after treatment), cause-specific survival (percentage of patients who had not died from disease under study in the 2 years since treatment), overall survival (percent of patients still alive at 2 years after treatment), and freedom from failure (percentage of patients in whom the disease treated had not progressed or recurred in the 2 years since treatment)</description>
        <time_frame>2 yrs</time_frame>
        <population>44 lesions in 38 patients were treated with IMRT or 3D conformal beams on a prospective trial examining thoracic SBRT. Twenty-two of 32 primary lung cancer patients had biopsy-proven NSCLC (stage IA, 21 patients; stage IB, 11 patients). Six had metastatic disease. Six patients had 2 lesions treated simultaneously.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients Receiving SBRT to the Thorax</title>
          </group>
        </group_list>
        <measure>
          <title>Disease Status</title>
          <description>2-year local control (Percentage of tumors that did not recur at treated site 2 years after treatment), cause-specific survival (percentage of patients who had not died from disease under study in the 2 years since treatment), overall survival (percent of patients still alive at 2 years after treatment), and freedom from failure (percentage of patients in whom the disease treated had not progressed or recurred in the 2 years since treatment)</description>
          <population>44 lesions in 38 patients were treated with IMRT or 3D conformal beams on a prospective trial examining thoracic SBRT. Twenty-two of 32 primary lung cancer patients had biopsy-proven NSCLC (stage IA, 21 patients; stage IB, 11 patients). Six had metastatic disease. Six patients had 2 lesions treated simultaneously.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rate of 2-year control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cause specific survival rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Survival rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from Failure rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity ot the Thorax</title>
        <description>Toxicity is defined as adverse events described in the CTCAE (version 3). Acute toxicity refers to adverse events that occurred up until 3 months after treatment and &quot;late&quot; toxicity as those occurring 3 months or longer after the end of treatment. Below are the Rates of grade 2 acute toxicity, grade 3 acute toxicity, late grade 3 toxicity, and late grade 4 toxicity</description>
        <time_frame>up to 2 years, 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients Receiving SBRT to the Thorax</title>
          </group>
        </group_list>
        <measure>
          <title>Toxicity ot the Thorax</title>
          <description>Toxicity is defined as adverse events described in the CTCAE (version 3). Acute toxicity refers to adverse events that occurred up until 3 months after treatment and &quot;late&quot; toxicity as those occurring 3 months or longer after the end of treatment. Below are the Rates of grade 2 acute toxicity, grade 3 acute toxicity, late grade 3 toxicity, and late grade 4 toxicity</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>grade 2 toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>grade 3 toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>late grade 2 toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>late grade 3 toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years, 9 months</time_frame>
      <desc>Adverse events were assessed every 3 weeks for 3 months and then every 3 months.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Patients Receiving SBRT to Thorax</title>
          <description>22 patients had Non-small-cell lung cancer (NSCLC), 6 had metastatic disease, and 6 had 2 lesions treated simultaneously.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Dyspnea</sub_title>
                <counts group_id="E1" events="24" subjects_affected="9" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 3 FEV1</sub_title>
                <counts group_id="E1" events="33" subjects_affected="17" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 4 FEV1</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 3 Vital Capacity</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 2 Esophagitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 1 Nausea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="16" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 2 Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Fatigue</sub_title>
                <counts group_id="E1" events="133" subjects_affected="29" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 2 Fatigue</sub_title>
                <counts group_id="E1" events="29" subjects_affected="13" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 cough</sub_title>
                <counts group_id="E1" events="85" subjects_affected="23" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 2 Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 1 Dyspnea</sub_title>
                <counts group_id="E1" events="77" subjects_affected="17" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 2 Dyspnea</sub_title>
                <counts group_id="E1" events="61" subjects_affected="11" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 1 FEV1</sub_title>
                <counts group_id="E1" events="16" subjects_affected="8" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 2 FEV1</sub_title>
                <counts group_id="E1" events="18" subjects_affected="7" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 1 Pleural Effusion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 1 Pneumonitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="10" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 2 Pneumonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 1 Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="10" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 2 Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 1 Vital Capacity</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 2 Vital Capacity</sub_title>
                <counts group_id="E1" events="43" subjects_affected="21" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Dermatitis</sub_title>
                <counts group_id="E1" events="41" subjects_affected="21" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grade 2 Dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bridget Fitzgerald, Clinical Research Coordinator</name_or_title>
      <organization>University of Florida</organization>
      <phone>352-265-0680 ext 87829</phone>
      <email>fitzgb@shands.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

